ATXI 外汇新闻

Specialty pharmaceutical company Avenue Therapeutics, Inc. (ATXI) announced Thursday that it has reached final agreement with the U.S. Food and Drug Administration on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint, for intravenous (IV) tramadol